Use of cell lines in the investigation of pharmacogenetic loci.
about
Pharmacogenomics discovery and implementation in genome-wide association studies eraExprtarget: an integrative approach to predicting human microRNA targetsPolymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.Impact of the 1000 genomes project on the next wave of pharmacogenomic discoveryBioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.Integrating heterogeneous high-throughput data for meta-dimensional pharmacogenomics and disease-related studiesIntegrating microRNAs into a system biology approach to acute lung injuryBioinformatics challenges for personalized medicinePopulation differences in microRNA expression and biological implications.The emerging role of microRNAs in drug responsesBioinformatic Resources of microRNA Sequences, Gene Targets, and Genetic Variation.Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications.Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers.Human lymphoblastoid cell lines: a goldmine for the biobankomics era.Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker.
P2860
Q27001573-B762F3F5-C843-423D-8969-F951194171AEQ28475891-B13C271E-7D31-42F4-95EC-9A854A0EB2ECQ30244222-4EFB366D-C08D-4FE1-9E4A-B860DC04AA43Q33708200-83FE85CF-2521-47EC-91BB-603B317CFF19Q33818738-EBEF9802-BBC4-484E-9B25-513C29996D15Q34132233-4BF213C5-3B3B-4C0B-8779-D5095492D15BQ34778041-501A289A-CBEA-4F58-9A4B-8FC12DC59234Q35051893-486392B3-1BB9-4EA7-991A-89C5BA1273ADQ35578546-2FD82E84-1167-4CF0-A08F-73B5457C04F4Q35599477-BC1596AE-73B7-4F00-A61A-0C6185F06E27Q35800946-575A655D-CF15-4EC5-9ADB-30F8BD11B439Q35820373-2D8B3730-0D0A-4362-ABF6-8D076BB281C0Q38121519-5282652C-DED5-44C8-BF5A-C1078E7B5D9BQ38748131-22516F68-5198-4C08-AEA5-4F3E9C95E9CFQ39293823-1800C3CC-FCF7-43AC-B292-D9489A6E5F28Q39520813-FE7CDAE0-1A03-4546-B553-2895C49A4974Q39589817-8DA2768D-515F-44F9-BCC7-755025B1A8D6
P2860
Use of cell lines in the investigation of pharmacogenetic loci.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of cell lines in the investigation of pharmacogenetic loci.
@en
Use of cell lines in the investigation of pharmacogenetic loci.
@nl
type
label
Use of cell lines in the investigation of pharmacogenetic loci.
@en
Use of cell lines in the investigation of pharmacogenetic loci.
@nl
prefLabel
Use of cell lines in the investigation of pharmacogenetic loci.
@en
Use of cell lines in the investigation of pharmacogenetic loci.
@nl
P2860
P1476
Use of cell lines in the investigation of pharmacogenetic loci.
@en
P2093
M Eileen Dolan
P2860
P304
P356
10.2174/138161209789649475
P577
2009-01-01T00:00:00Z